FDA Approves Jaypirca for Frontline CLL/SLL

JaypircaWhat to know

30-second read

For Hematology · Oncology

Who

Adults with previously untreated CLL or SLL confirmed free of a 17p deletion — patients who would otherwise start chemoimmunotherapy or a covalent BTK inhibitor.

What’s new

Pirtobrutinib (Jaypirca), approved for later-line CLL/SLL since 2023, now has full approval as initial therapy — the first non-covalent BTK inhibitor approved first-line.

Evidence

BRUIN CLL-313: 282 treatment-naive patients randomized to pirtobrutinib or six cycles of bendamustine-rituximab. Median PFS not reached vs. 33.5 months (HR 0.20).

Big advantage

An estimated 80% reduction in the hazard of progression or death versus chemoimmunotherapy, with continuous oral once-daily dosing and no cytotoxic exposure.

Key consideration

Confirm no 17p deletion first — the trial excluded it. Infections, cytopenias, hemorrhage and AFib/flutter appear in labeling; this is indefinite therapy, not a fixed course.

Availability

Already marketed since 2023. ∼$22,050 wholesale per 28-day supply; a commercial savings card exists; payer coverage for this larger frontline population is still forming.

Practice impactConsider for selected patients

A genuine option for treatment-naive, 17p-deletion-negative patients who want to avoid chemotherapy or carry cardiac risk factors that make covalent BTK inhibitors less appealing. It has not been shown superior to the BTK inhibitors already used first-line.

Read the full physician analysis

Full analysis · 10 min readFDA approval notice · Jaypirca prescribing information · BRUIN CLL-313 (ASCO Post, October 2026)

The FDA approved Jaypirca (pirtobrutinib), Eli Lilly’s oral BTK inhibitor, on 2 October 2026 for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a 17p deletion — its first approval as initial therapy after three years as a later-line option. It is the first non-covalent BTK inhibitor to reach the frontline setting, joining two covalent BTK inhibitors and a fixed-duration venetoclax combination as first-line choices.

Who the new indication covers, and who it doesn’t

The label is narrower than “untreated CLL/SLL.” BRUIN CLL-313 enrolled only patients confirmed free of a 17p deletion, randomizing 282 of them 1:1 to pirtobrutinib monotherapy, taken until progression, or six cycles of bendamustine plus rituximab. Randomization was stratified by IGHV mutation status and Rai stage, and the benefit held across both IGHV-mutated and IGHV-unmutated subgroups — but del(17p) patients were never in the trial, so the approval’s evidence base simply does not reach them. FISH or next-generation sequencing for del(17p)/TP53 status is the practical gate before offering pirtobrutinib as frontline monotherapy, the same testing step oncologists already run before choosing any first-line CLL regimen.

A BTK inhibitor that doesn’t bind the way the others do

Ibrutinib, acalabrutinib and zanubrutinib are covalent inhibitors: they form an irreversible bond at BTK’s Cys481 residue. Pirtobrutinib is non-covalent and reversible, binding independently of Cys481 at a dose of 200 mg once daily that the manufacturer says achieves roughly 96% steady-state BTK occupancy, with a circulating half-life of about 20 hours. The practical consequence is twofold: pirtobrutinib retains activity against some resistance mutations that arise against covalent inhibitors, which is why it was first approved for patients who had already progressed on one, and its once-daily oral dosing does not require the ramp-up or tumor-lysis precautions that come with venetoclax. Whether that mechanism translates into a durability advantage over covalent BTK inhibitors specifically — rather than over chemoimmunotherapy — is not something BRUIN CLL-313 was designed to answer.

What BRUIN CLL-313 actually measured

The trial’s comparator was chemoimmunotherapy, not another targeted agent. At an estimated median follow-up of 28 months, median progression-free survival was not reached in the pirtobrutinib arm versus 33.5 months on bendamustine-rituximab, a hazard ratio of 0.20 — an estimated 80% reduction in the risk of progression or death. Overall survival was a key secondary endpoint; FDA’s approval was not conditioned on it reaching statistical significance, and Lilly has said a formal OS analysis is still maturing. A separate, smaller pooled analysis presented at the 2026 EHA Congress — combining the randomized CLL-313 cohort with a single-arm cohort from the related BRUIN CLL-314 study — reported a 93.3% overall response rate and 24-month progression-free survival of 93.2%, figures that support the picture but were not themselves the approval’s regulatory basis.

BRUIN CLL-313 at a glance

282Treatment-naive CLL/SLL patients, randomized 1:1, all confirmed free of a 17p deletion

HR 0.20Hazard ratio for progression-free survival, pirtobrutinib vs. bendamustine-rituximab

Not reached vs. 33.5 moMedian progression-free survival at an estimated 28-month follow-up

27% · 22% · 21%Most common adverse reactions: upper respiratory infection, rash, COVID-19

From the FDA approval notice and Jaypirca prescribing information, 2 October 2026.

Where it sits beside the first-line options already in use

Three ways to start treatment-naive CLL/SLL

	Jaypirca (pirtobrutinib)	Covalent BTK inhibitors	Venetoclax + obinutuzumab
FDA frontline basis	BRUIN CLL-313 vs. bendamustine-rituximab, approved 2 Oct 2026	Acalabrutinib (ELEVATE-TN) and zanubrutinib, each already FDA-approved first-line	CLL14, a fixed 12-cycle regimen, already FDA-approved first-line
Mechanism	Non-covalent, reversible BTK inhibitor	Covalent, irreversible BTK inhibitors (bind Cys481)	BCL-2 inhibitor plus an anti-CD20 antibody; no BTK involvement
Duration	Continuous, until progression or intolerance	Continuous, until progression or intolerance	Fixed 12 months, then a treatment-free interval
17p deletion / TP53	Excluded from the registration trial — label basis is del(17p)-negative patients	FDA-approved across risk groups, including del(17p)	FDA-approved across risk groups, including del(17p)
Notable safety signals (per label)	Infections, cytopenias, hemorrhage, atrial fibrillation/flutter	Cardiac arrhythmia and bleeding risk are class effects of covalent BTK inhibition	Tumor lysis syndrome risk during the dose ramp-up; no BTK-related cardiac signal

Each regimen’s figures come from its own FDA label and registration trial, not a head-to-head comparison — prescribe from the current label, not this table.

The safety label carried over from later-line use

Pirtobrutinib carries no boxed warning, but its warnings and precautions are substantial, unchanged by the new indication. Grade 3 or higher infections occurred in 24% of patients across the drug’s trials, most commonly pneumonia (14%), with fatal infections in 4.4%; prophylaxis and vaccination should be considered for patients at elevated risk. Major hemorrhage occurred in 3%, fatal hemorrhage in 0.3%. Atrial fibrillation or flutter occurred in 2.7% of patients, Grade 3 or 4 in 1% — a signal to weigh specifically in older CLL patients with existing cardiac risk factors, the population this approval newly reaches. Grade 3 or 4 cytopenias included neutropenia in 24% (Grade 4 in 13%), anemia in 11% and thrombocytopenia in 11% (Grade 4 in 5%); the label also lists second primary malignancies and hepatotoxicity. None of this is new to Jaypirca’s label — it is simply now relevant to a much larger population choosing a first drug rather than a last option.

Cost and coverage for a population that just got much bigger

Jaypirca does not need a launch; it has been on specialty-pharmacy shelves since its 2023 mantle-cell-lymphoma approval. Wholesale acquisition cost runs around $22,050 for a 28-day supply at the 200 mg daily dose (two 100 mg tablets), with a 50 mg tablet available for dose reductions. Lilly’s savings card can reduce out-of-pocket cost for commercially insured patients; Medicare Part D and commercial-payer prior-authorization policies written for a narrow, post-BTK-inhibitor population will need to be rewritten for a treatment-naive one, and that rewriting has not yet happened at most plans. Unlike venetoclax-obinutuzumab’s fixed 12-month course, pirtobrutinib is taken indefinitely, which changes the practice’s long-run exposure to prior-authorization renewals as much as it changes the patient’s pill burden.

What changes in the clinic

• Testing before treatment. FISH or NGS for del(17p)/TP53 is the gate for pirtobrutinib monotherapy; IGHV mutation status is informative for prognosis but did not exclude patients from benefit in the trial.
• Sequencing conversations move earlier. A continuous oral BTK inhibitor versus a fixed 12-month venetoclax-obinutuzumab course is now a first-line discussion, not just a relapse discussion — patient preference about treatment-free intervals matters at diagnosis.
• Cardiac history review. Atrial fibrillation risk, while reported as comparatively low in Jaypirca’s own label, is still a factor to weigh against covalent BTK inhibitors in older patients with existing arrhythmia or hypertension.
• Monitoring. Baseline and periodic CBCs, infection vigilance, and liver function tests follow from the same warnings that applied to later-line use.
• Access workload. Expect new prior-authorization friction as a treatment-naive population, with its own utilization-management rules, replaces the narrower post-BTK-inhibitor population plans have covered since 2023.

BRUIN CLL-313 proves pirtobrutinib beats chemoimmunotherapy in previously untreated, 17p-deletion-negative CLL/SLL. It does not prove pirtobrutinib beats the BTK inhibitors oncologists already prescribe first-line, because no trial has compared them head-to-head. Until one does, or until mature overall-survival data arrive, this approval adds a third first-line pathway rather than settling which one goes first. Every story on this desk is filed by specialty on the For Physicians front.

From third-line rescue to first-line option

1. Jan 2023

   First approval

   Accelerated approval for relapsed/refractory mantle cell lymphoma after a BTK inhibitor.

2. Dec 2023

   CLL/SLL, third line

   Accelerated approval after at least two prior lines, including a BTK and a BCL-2 inhibitor.

3. Dec 2025

   Traditional approval

   Converted to full approval for relapsed/refractory CLL/SLL after a covalent BTK inhibitor.

4. 2025–2026

   BRUIN CLL-313 reads out

   Meets its primary progression-free-survival endpoint against chemoimmunotherapy in treatment-naive patients.

5. 2 Oct 2026

   Frontline approval

   FDA approves pirtobrutinib as initial therapy for untreated, 17p-deletion-negative CLL/SLL.

6. Ahead

   Overall survival and sequencing data

   A mature OS analysis, and any head-to-head trial against covalent BTK inhibitors or venetoclax-obinutuzumab, would settle where it ranks rather than just that it qualifies.

Frequently asked questions

Does every treatment-naive CLL/SLL patient qualify for pirtobrutinib?

No. The approval covers only patients confirmed free of a 17p deletion — BRUIN CLL-313 excluded del(17p) patients entirely, so the label's evidence base does not extend to them. FISH or NGS testing for del(17p)/TP53 status before choosing first-line therapy is the gate, not a formality.

Is pirtobrutinib now the preferred first-line option over acalabrutinib, zanubrutinib or venetoclax-obinutuzumab?

That hasn't been shown. BRUIN CLL-313 compared pirtobrutinib against chemoimmunotherapy (bendamustine-rituximab), not against the BTK inhibitors or fixed-duration regimens oncologists already use first-line. The approval adds an option; it does not settle sequencing.

How is pirtobrutinib different from ibrutinib, acalabrutinib or zanubrutinib?

Those three bind BTK covalently at the Cys481 residue. Pirtobrutinib binds reversibly, independent of Cys481, which is why it still works against some BTK resistance mutations that emerge on covalent inhibitors and is why its safety profile in labeling looks comparatively favorable — though that comparison comes from separate trials, not a head-to-head study.